1. Volume 2, Issue 6, Pages e243-e251 (June 2015)
Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland 
Dr Rishi K Gupta, MRCP, Brian Rice, MSc, Alison E Brown, PhD, H Lucy Thomas, MFPH, Dominik Zenner, MD, Laura Anderson, PhD, Debora Pedrazzoli, MSc, Anton Pozniak, MD, Prof Ibrahim Abubakar, FRCP, Valerie Delpech, FFPH, Marc Lipman, MD 
The Lancet HIV 
Volume 2, Issue 6, Pages e243-e251 (June 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Study entry and exit of individuals in HIV-positive cohort in England, Wales, and Northern Ireland, 2007–11
The Lancet HIV 2015 2, e243-e251DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Tuberculosis incidence by months on antiretroviral therapy in the national HIV cohort in England, Wales, and Northern Ireland
Error bars represent 95% CIs.
The Lancet HIV 2015 2, e243-e251DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3
Tuberculosis incidence in national HIV cohort compared with that in background HIV-negative population in 2009
Data shown for patients with HIV receiving antiretroviral therapy and with most recent CD4 count of at least 500 cells per μL; background HIV-negative incidence for 2009.
The Lancet HIV 2015 2, e243-e251DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions